DBV Technologies | DBVT - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Acadia Pharmaceuticals USD 272.68M 6.08M 2026-03
Alnylam Pharmaceuticals USD 1.06B 160.97M 2026-06
Amarin USD 51.48M 113K 2025-12
BioCryst Pharmaceuticals USD -553.84M 700.01M 2026-03
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
DBV Technologies USD 47.9M 2.2M 2026-03
Galectin Therapeutics USD 11.29M 1.64M 2024-06
Halozyme Therapeutics USD 192.19M 18.88M 2026-03
Incyte USD 973.64M 4.65B 2026-06
Insmed USD 506.24M 7.31M 2026-03
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
Neurocrine Biosciences USD 739.1M 139.2M 2026-06
PTC Therapeutics USD 226.66M 19.64M 2026-03
Sarepta Therapeutics USD 372.37M 480.65M 2026-03
Ultragenyx Pharmaceutical USD 305M 16M 2026-03
United Therapeutics USD 5.9B 5.1B 2026-03